In a previous posting, we flagged how the BIOSECURE Act (enacted as Section 851 of the Fiscal Year 2026 National Defense Authorization Act) reflects a growing focus on biotechnology supply chains within federal procurement. The statute is designed around a simple premise: Biotechnology risks rarely appear at the level of the final product. Instead, the risks tend to emerge through tools, platforms, and service providers embedded in the performance of federally funded work.

Nowhere is that observation more apparent than in industries adjacent to biotechnology that rely heavily on biological data, specialized testing infrastructure, or outsourced research capabilities. Examples include pharmaceutical and biologics developers, medical device and diagnostics manufacturers, contract research organizations (CROs) and specialized laboratory providers, healthcare and academic research institutions participating in federally funded programs, and technology companies supporting biological data analytics or laboratory automation. For these sectors, biotechnology may not define the business model, but it plays a quiet yet significant operational role in how products are discovered, validated, and manufactured. The BIOSECURE Act brings those operational dependencies into sharper focus.

Where the Act Meets the Life Sciences Ecosystem

Section 851 establishes a government-wide framework prohibiting agencies from procuring biotechnology equipment or services from entities designated as “biotechnology companies of concern.” It also bars agencies from awarding/renewing contracts, grants, or loans to/with entities that rely on such equipment or services in the performance of federally funded work. The breadth of the statute’s definition is significant, with “Biotechnology equipment or service” including not only laboratory instruments but also software and services used to research, develop, analyze, manufacture, detect, or process biological materials or biological data.

In practice, this means that BIOSECURE Act exposure may arise through infrastructure that many organizations treat as routine operational support. Bioinformatics platforms analyzing biological datasets, third-party laboratories performing validation or testing, sequencing services, laboratory automation systems, and cloud-based analytics environments can all fall within the statute’s scope. For organizations operating in research-intensive industries, those capabilities are increasingly integrated into day-to-day operations.

Outsourced Research Infrastructure and Indirect Exposure

One of the defining features of modern biomedical development is the reliance on specialized external partners. CROs, testing laboratories, sequencing providers, and analytics platforms often support work that ultimately feeds into federally funded programs. As our earlier “Government Contractor” analysis observed, biotechnology tools often sit within automated systems, outsourced services, or analytics platforms that are several layers removed from the teams responsible for managing federal contracts or regulatory compliance.

This structure creates a very real and practical challenge. Relationships that were originally selected for technical capability or operational efficiency may later become relevant from a federal supply chain perspective. In many cases, those dependencies were never mapped through a procurement compliance lens because they were treated as background scientific infrastructure. That distance collapses with the BIOSECURE Act.

When Infrastructure Becomes a Certification Issue

Looking ahead, the BIOSECURE Act will arrive through a designation process led by the Office of Management and Budget, followed by amendments to the Federal Acquisition Regulation. Once those regulatory steps occur, contractors should expect to find representations and certifications regarding their use of biotechnology equipment or services connected to designated companies. At that stage, what was once an operational infrastructure issue may become a compliance issue.

For research-driven organizations, this dynamic raises a practical question: How should companies certify compliance when biological data processing, laboratory testing, and analytical platforms are often shared across multiple programs? In many environments, scientific computing systems, laboratory informatics platforms, and external laboratory services support a mix of federally funded and purely commercial work. So the challenge becomes defining the operational boundary of the certification with precision. Overly broad representations risk creating enterprise-wide obligations that may be impossible to support, while overly narrow representations may be questioned during audits or investigations.

Nothing in the present state of the statute resolves that operational issue. As a result, organizations will need to develop internal frameworks that map how federally connected work interacts with shared technical infrastructure.

Federal Assistance and Downstream Funding Relationships

Another important aspect of the BIOSECURE Act is that its reach is not limited to traditional procurement contracts. The statute also applies to federal grants and loans, meaning BIOSECURE Act requirements may appear through assistance agreements, cooperative research arrangements, and subawards. For many organizations, this may be the first place the issue surfaces. Research networks, academic collaborations, clinical research partnerships, and other funding arrangements often involve multiple participants operating within shared scientific infrastructure. In settings like these, compliance questions could arise even when the organization doesn’t consider itself a “federal contractor” in the more traditional sense.

Vendor Designations and Operational Continuity

Another scenario that warrants planning involves the designation of a vendor as a “biotechnology company of concern” after a contract or research program has already begun. Although the statute provides for phased implementation through regulatory rulemaking, vendor designations can still create operational challenges after compliance obligations attach. Organizations may need to evaluate the availability of alternative suppliers, assess the role of the designated vendor in ongoing research workflows, and determine when disclosure to or coordination with a contracting officer or funding agency may be required. A “single point of failure” should be identified and flagged as a potential risk. Enhancing that risk is the fact that scientific programs, regulatory commitments, and contractual obligations often intersect, meaning that supplier changes can have implications for timelines, validation activities, and ongoing research programs.

Contractual Infrastructure and Supply Chain Visibility

Because many biotechnology-enabled capabilities are delivered through external vendors, BIOSECURE Act compliance is likely to depend on contractual relationships that were originally negotiated without supply chain restrictions in mind. Organizations may find that existing master services agreements with research partners, testing laboratories, analytics providers, or manufacturing support vendors lack the soon-to-be-necessary provisions addressing issues such as ownership disclosures, designation notifications, audit rights, and transition support if a vendor becomes restricted. In practical terms, compliance may require not only internal diligence but adjustments to the contractual architecture governing key research and testing relationships.

Preparing for the BIOSECURE Act Compliance Horizon

Although implementing regulations are still forthcoming, organizations operating in the broader life sciences ecosystem can begin preparing now by improving visibility into the scientific and technical infrastructure supporting federally connected work. Companies should consider taking steps to do the following:

• Map biotechnology-enabled vendors across research and development activities. Identify CROs, testing laboratories, sequencing providers, and analytics platforms that handle biological materials or data in connection with federally funded work.
• Understand how biological data and laboratory systems are shared across programs. Many CROs rely on shared scientific computing environments, laboratory informatics platforms, and external laboratory partners that support both federal and commercial workstreams.
• Evaluate vendor ownership and national security risk indicators. Early diligence on vendor ownership structures and foreign influence risks may help organizations anticipate potential designation issues.
• Review contractual frameworks with key scientific vendors. Master services agreements with research partners, testing laboratories, and analytics providers may need to incorporate provisions addressing supply chain restrictions, disclosure obligations, and potential transition requirements.
• Develop internal coordination between legal, compliance, procurement, and research teams. BIOSECURE Act compliance will likely require collaboration between government contracts counsel, regulatory teams, and the scientific functions responsible for selecting research tools and service providers.

Preparing for a Broader Policy Shift

For organizations operating within—or alongside—the life sciences ecosystem, the BIOSECURE Act and the government’s shifting emphasis on supply chain visibility, industrial base resilience, and foreign influence risks across multiple sectors suggest that biological data systems, laboratory services, and research platforms will increasingly be viewed through a national security lens. For companies whose operations rely on complex research partnerships and global scientific infrastructure, understanding those connections early may prove far easier than trying to reconstruct them once formal certification obligations arrive.